AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine
In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to BRAF and/or MEK inhibition.
Check out our comprehensive panel of PDX models
4988_A tailored platform enables BRAF-targeted drug discovery and precision medicine_final - Copy
Related Content
What if a constructed PROTAC with a confirmed high-affinity warhead doesn't work as expected? That means we need to take...
VIEW RESOURCEFragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...
VIEW RESOURCE